In the midst of the rapid development of novel antibody therapies and the “new normal” of the pandemic, the Chinese Antibody Society (CAS) will hold the 2022 Annual Conference in Boston on October 30, 2022 (Sunday). This will be the first in-person event of the Chinese Antibody Society since the pandemic started. The topic of the CAS 2022 Annual Conference is: “AntibodyPlus: next generation antibody-based biologics.” The Chinese Antibody Society will continue to provide a platform for accelerating antibody-based therapies research and development, and will strive to make an active contribution to the global therapeutic antibody research and development community.

AntibodyPlus™ is a new concept developed by the Chinese Antibody Society to cover various antibody-derived therapeutic compounds and drugs, e.g., direct fusion/coupling of therapeutic agents to antibodies, gene therapies that express antibodies through mRNA, DNA plasmids, etc. The evolution from the monoclonal antibody to AntibodyPlus™ reflects the rapid development and innovation in the therapeutic antibody field. The CAS 2022 Annual Conference will primarily focus on the research frontier of antibody therapies, the latest development of technologies in this field, and the opportunities in the global antibody research field.